Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets
The Firm’s Ranibizumab Biosimilar FYB201 Is Already Available In 17 Countries
Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.
